Delcath Systems, Inc. (DCTH) company profile
Close on Nov 18, 2026Market cap $683.57MP/E 1970.0Yield –
About Delcath Systems
Surgical & Medical Instruments & Apparatus, SIC 3841
Delcath Systems, Inc. is an interventional oncology company that specializes in treatments for primary and metastatic liver cancers. The company operates through a single business segment and develops liver-directed therapies designed to administer chemotherapy directly to the liver while restricting systemic exposure. Its primary commercial offerings include the HEPZATO KIT, an FDA-approved drug and device combination, and CHEMOSAT, a stand-alone hepatic delivery medical device marketed in Europe. Delcath provides these systems primarily to specialized cancer centers, hospital radiology departments, and treating oncologists caring for adult cancer patients.
The company conducts commercial and clinical activities across the United States and Europe. In the United States, Delcath has twenty-five active cancer center sites and thirty-two facilities accepting patient referrals. In Europe, its medical device is available in twenty-two cancer centers and has been administered in over two thousand commercial procedures. The company maintains its corporate headquarters in Queensbury, New York.
Summary of the business section of Delcath Systems's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Delcath Systems, Inc.
- Founded
- 1988
- Headquarters
- Queensbury, NY
- Address
- 566 Queensbury Avenue 12804
- Phone
- (518) 743-8892
- Website
- delcath.com
- Employees
- 156, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, New York, NY
Stock & identifiers
- Ticker
- DCTH
- Exchange
- Nasdaq
- IPO date
- May 3, 2018
- Shares outstanding
- 35M, Jul 31, 2026
- Public float
- $419.74M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-700 reverse, Dec 24, 2019; 1-for-350 reverse, Nov 6, 2017; 1-for-16 reverse, Jul 21, 2016; 1-for-16 reverse, May 7, 2014
- SEC CIK
- 872912
- CUSIP
- 24661P807
- ISIN
- US24661P8077
- FIGI
- BBG000BY2VF5
- Share class FIGI
- BBG001S81551
- LEI
- 549300NVPLITUM6URT02
- EIN
- 06-1245881
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Gerard J. Michel | CHIEF EXECUTIVE OFFICER, Director | 342,034 |
| Sandra Pennell | Chief Financial Officer | 77,018 |
| David L. Hoffman | GEN'L COUNSEL, CCO & SECY | 74,330 |
| Vojo Vukovic | CHIEF MEDICAL OFFICER | 168,882 |
| Kevin Muir | GM INTERVENTIONAL ONCOLOGY | 18,582 |
| Martha S. Rook | CHIEF OPERATING OFFICER | – |
| Bridget A. Martell | Director | 0 |
| Rosalind Advisors, Inc. | Director | 3,389,593 |
| Gil Aharon | Director | 4,483,178 |
| Steven A. J. Salamon | Director | 4,534,493 |
| John Richard Sylvester | Director | 14,936 |
| Elizabeth Czerepak | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $5.77M | $3.11M | $2.04M | $281 | – |
| FY2024 | $2.16M | $4.88M | $1.01M | $334 | – |
| FY2023 | $2.52M | $2.15M | $1.11M | $116 | – |
| FY2022 | $1.47M | -$188.10K | $770.92K | $46 | – |
| FY2021 | $1.91M | -$2.08M | $900.63K | $44 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Total | vs. prior year |
|---|---|---|---|---|---|
| Gerard Michel Chief Executive Officer | $635.71K | $4.77M | $355.00K | $5.77M | +167% |
| Vojislav Vukovic Chief Medical Officer | $488.00K | $1.38M | $184.00K | $2.06M | +89% |
| Martha Rook Chief Operating Officer | $460.83K | $1.38M | $180.00K | $2.02M | +117% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of February 13, 2026, including our management team, we had approximately 156 full time employees, of which 141 are located in the United States and 15 are located in Europe.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?